COMPLEXO: identifying the missing heritability of breast cancer via next generation collaboration by Soucy, P et al.
Title COMPLEXO: identifying the missing heritability of breast cancervia next generation collaboration
Author(s) Southey, M; Park, D; Campbel, I; Thompson, E; Simard, J;Dumont, M; Soucy, P; Kwong, A
Citation Breast Cancer Research, 2013, v. 15 n. 3, p. article no. 402
Issued Date 2013
URL http://hdl.handle.net/10722/186355
Rights Breast Cancer Research (Online Edition). Copyright © BioMedCentral Ltd.
Linkage analysis, positional cloning, candidate gene 
muta tion scanning and genome-wide association study 
approaches have all contributed signifi cantly to our 
understanding of the underlying genetic architecture of 
breast cancer. Taken together, these approaches have 
identifi ed genetic variation that explains approximately 
30% of the overall familial risk of breast cancer, implying 
that more, and likely rarer, genetic susceptibility alleles 
remain to be discovered.
Th e application of massively parallel sequencing has 
further demonstrated the complexity of human genetic 
variation and has raised many challenges for 
computational and statistical methods for searching for 
additional breast cancer predisposition genes. Early 
fi ndings are consistent with previous indications that no 
single gene is likely to account for a large proportion of 
the remaining unexplained genetic susceptibility [1,2].
Coordinated international collaboration off ers great 
potential to advance the discovery of additional breast 
cancer susceptibility genes by increasing the likelihood of 
identifying functionally relevant genetic variants in the 
same genes in multiple families. A new consortium, 
COMPLEXO (a name chosen to refl ect the complexity of 
the exome), has been formed to facilitate collaborations 
between researchers actively applying massively parallel 
sequencing to understand the genetics of breast and 
ovarian cancer. Th e consortium has defi ned activities 
aimed at bringing together data and resources suitable 
for exome/genome sequencing initiatives and for large 
case-control-family study resources suitable for valida-
tion of candidate susceptibility genes in which rare muta-
tions are associated with high to moderate risk of breast 
cancer. Th e aim of COMPLEXO is to bring to massively 
parallel sequencing the same power of large sample sets 
that have proven so successful in examining the role of 
common variants in cancer populations via the con sor-
tium model, such as the Breast Cancer Association 
Consortium (BCAC), the Consortium of Investigators of 
Modifi ers of BRCA1/2 (CIMBA), the Ovarian Cancer 
Association Consortium (OCAC) and the Collaborative 
Oncology Gene-environment Study (COGS) [3-5]. How-
ever, sequencing studies provide additional challenges in 
terms of defi ning specifi c modes of collaboration given 
diff erences in sequencing and targeted capture platforms, 
bioinformatics platforms, the need to integrate ongoing 
studies in many centers and socio-ethical-legal issues that 
are not as relevant to initiatives that are genotyping 
common genetic variation.
COMPLEXO invites collaboration from any researcher 
who would like to contribute to this consortium either by 
contributing data to the combined COMPLEXO data set, 
contributing resources for large-scale validation of candi-
date breast cancer predisposition genes or refi ning analy-
tical and bioinformatic pipelines for massively parallel 
sequencing data fi ltering and prioritization. COMPLEXO 
also has interests in the critical assessment of current 
platforms and protocols and in developing and improving © 2010 BioMed Central Ltd
COMPLEXO: identifying the missing heritability of 
breast cancer via next generation collaboration
COMPLEXO: Melissa C Southey1*, Daniel J Park1, Tu Nguyen-Dumont1, Ian Campbell2, Ella Thompson2, Alison H Trainer3, 
Georgia Chenevix-Trench4, Jacques Simard5, Martine Dumont5, Penny Soucy5, Mads Thomassen6, Lars Jønson7, 
Inge S Pedersen8, Thomas VO Hansen7, Heli Nevanlinna9, Sofi a Khan9, Olga Sinilnikova10,11, Sylvie Mazoyer10, 
Fabienne Lesueur12, Francesca Damiola10, Rita Schmutzler13,14, Alfons Meindl15, Eric Hahnen13,14, Michael R Dufault15, 
TL Chris Chan16,17, Ava Kwong16,18, Rosa Barkardóttir19, Paolo Radice20, Paolo Peterlongo21, Peter Devilee22, 
Florentine Hilbers22, Javier Benitez23, Anders Kvist24, Therese Törngren24, Douglas Easton25, David Hunter26, 
Sara Lindstrom26, Peter Kraft26, Wei Zheng27, Yu-Tang Gao28, Jirong Long27, Susan Ramus29, Bing-Jian Feng30, 
Jeff rey N Weitzel31, Katherine Nathanson32, Kenneth Offi  t33, Vijai Joseph33, Mark Robson33, Kasmintan Schrader33, 
San Ming Wang34, Yeong C Kim34, Henry Lynch35, Carrie Snyder35, Sean Tavtigian36, Susan Neuhausen37, 
Fergus J Couch38 and David E Goldgar36
LETTER
*Correspondence: msouthey@unimelb.edu.au
1Genetic Epidemiology Laboratory, Department of Pathology, The University of 
Melbourne, Victoria 3010, Australia
Full list of author information is available at the end of the article
Southey et al. Breast Cancer Research 2013, 15:402 
http://breast-cancer-research.com/content/15/3/402
© 2013 BioMed Central Ltd
data fi ltering and gene prioritization strategies to 
enhance gene discovery initiatives. Th ese approaches are 
relevant to all complex human diseases.
Interested researchers can engage with COMPLEXO 
via any local member or by contacting the corresponding 
author.
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